Kairos Venture Investments, LLC has made headlines with its recent filing regarding significant transactions involving warrants for Actuate Therapeutics, Inc. This move is noteworthy as it underscores the ongoing engagement of venture capital firms in the pharmaceutical sector, particularly in biotechnology.

The filing, made on November 2, 2026, reveals that Kairos Venture Investments is actively involved in the management of several funds that have acquired warrants from Actuate Therapeutics. This strategic investment could indicate a growing confidence in the potential of Actuate, which operates in the pharmaceutical preparations sector.

Background

Kairos Venture Investments, LLC, based in Beverly Hills, California, is a venture capital firm involved in various investment activities. The firm is linked to several limited partnerships, including Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and others. These partnerships focus on investing in innovative companies, particularly in the life sciences sector.

Actuate Therapeutics, Inc., the issuer in this transaction, is categorized under the Pharmaceutical Preparations industry (SIC 2834). The company's focus on therapeutic solutions positions it as a significant player in the biotech landscape.

What the Filing Says

The recent filing disclosed that on October 28, 2026, the Kairos Funds acquired warrants to purchase a total of 700,000 shares of Actuate's common stock. The warrants have an exercise price of $0.5325 per share and are immediately exercisable. The filing states, "The securities of Actuate Therapeutics, Inc. that are reported herein are held directly by Kairos-Actuate SPV, L.P., Kairos Venture Partners II, L.P., Kairos Venture Opportunities I, L.P., and Kairos SPV Fund, LLC (collectively, the 'Kairos Funds')."

Impact

This development may have significant implications for various stakeholders. The transactions indicate a robust interest from venture capital in the pharmaceutical sector, particularly in companies like Actuate that are focused on therapeutic innovations. Investors and analysts will likely be monitoring how these investments impact Actuate's market positioning and growth trajectory.

Moreover, the relationship between Kairos Venture Investments and Actuate Therapeutics, as highlighted in the filing, suggests a collaborative approach that could foster further advancements in drug development and commercialization.

What's Next

While the filing does not specify future actions, the acquisition of these warrants indicates that the Kairos Funds are committed to their investment in Actuate. Observers will be keen to see how this partnership evolves and whether it leads to additional funding rounds or strategic collaborations in the future.

This update serves as a reminder of the dynamic nature of the pharmaceutical industry, where strategic investments can significantly influence market trends and company trajectories.